Efficacy and safety of pharmacological therapy of obesity in liver transplant candidates

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-526044-12-00

Enrollment

Registered

2026-03-18

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

Absolute and relative change in body weight/BMI/body fat composition during the follow-up period.

Detailed description

Occurrence of complications while on the waiting list (WL) related to the underlying liver disease, Safety of treatment (adverse events), Post-transplant complications (1M, 3M, 6M), Patient survival (1M, 3M, 6M), Graft survival (1M, 3M, 6M)

Interventions

DRUGMounjaro 5 mg solution for injection in pre-filled pen

DRUGMounjaro 2.5 mg solution for injection in pre-filled pen

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Absolute and relative change in body weight/BMI/body fat composition during the follow-up period.	—

Secondary

Measure	Time frame
Occurrence of complications while on the waiting list (WL) related to the underlying liver disease, Safety of treatment (adverse events), Post-transplant complications (1M, 3M, 6M), Patient survival (1M, 3M, 6M), Graft survival (1M, 3M, 6M)	—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 19, 2026